Abstract: A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA,comprising silicon nanoparticles, at least one amino acid,and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.

Abstract: Encapsulated particles comprising one or more particle cores of silicon-containing material, wherein the one or more particle cores are encapsulated in a waxy lipid shell comprising: a) two lipidic components present at from 55% to 95% of the total encapsulated particle weight; b) a surfactant present at from 0.1% to 5% by weight of the total encapsulated particle weight; c) a co-surfactant present at from 0.01% to 1% by weight of the total encapsulated particle weight; d)a regulator of metastable state present at from 0.1% to 5% by weight of the total encapsulated particle, wherein the regulator of metastable state is selected from one or more of: the terpenes; the terpenoids; fatty acids, from myristic to docosanoic, pegylated by methyl ether of polyethylene glycol (PEG. Me M. W. 750-2000); diacylphosphatidylethanolamines pegylated with PEG;poloxamers (Pluronics); and derivatives thereof. Also related compositions and methods.

Abstract: A method for stabilizing a bioactive herbaceous extract in a composition comprising silicon particles, the method comprising bringing the bioactive herbaceous extract into contact with the silicon particles, in the presence of at least one non-reducing disaccharide. Also related compositions and methods.

Abstract: Pharmaceutically compatible nanoparticles comprising at least 50% by weight hydrolysable silicon, wherein the nanoparticles are surface coated with a phospholipid, and wherein the coated nanoparticlesare associated with fluorouracil. Also related compositions and methods.